{"id":"bat3306","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BAT3306 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing the immune response against cancer cells.","oneSentence":"BAT3306 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:21.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07180862","phase":"PHASE1","title":"A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants","status":"RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2025-10-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":140},{"nctId":"NCT06280196","phase":"PHASE3","title":"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC","status":"TERMINATED","sponsor":"Bio-Thera Solutions","startDate":"2024-07-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":162},{"nctId":"NCT06111196","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2023-11-05","conditions":"Healthy Male Subjects","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pembrolizumab Injection"],"phase":"phase_3","status":"active","brandName":"BAT3306","genericName":"BAT3306","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAT3306 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}